For the quarter ending 2025-09-30, VIR had -$127,022K decrease in cash & cash equivalents over the period. -$167,887K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -163,141 | -231,923 |
| Depreciation and amortization | 2,998 | 5,784 |
| Amortization of premiums on investments, net | -1,315 | -6,610 |
| Noncash lease expense | 1,297 | 2,358 |
| Change in fair value of equity investments | -1,335 | -3,000 |
| Change in estimated fair value of contingent consideration | 560 | 11,010 |
| Payment of contingent consideration in excess of acquisition date fair value | 0 | -17,140 |
| Stock-based compensation | 11,356 | 26,510 |
| In-process research and development impairment | 0 | 0 |
| Long-lived assets impairment and disposal loss | 0 | 399 |
| Other non-cash items, net | 40 | 59 |
| Prepaid expenses and other current assets | -4,215 | -5,937 |
| Other assets | 2,792 | 1,132 |
| Accounts payable | -5,402 | 7,444 |
| Accrued liabilities and other long-term liabilities | -14,155 | -5,458 |
| Operating lease liabilities | -1,792 | -3,253 |
| Deferred revenue | -675 | -2,540 |
| Net cash used in operating activities | -167,570 | -198,335 |
| Proceeds from sale of equipment | 37 | 326 |
| Purchases of long-lived assets | 317 | 4,167 |
| Purchases of investments | 264,447 | 366,065 |
| Maturities and sales of investments | 305,173 | 553,180 |
| Net cash provided by investing activities | 40,446 | 183,274 |
| Proceeds from exercise of stock options | 101 | 1,247 |
| Issuance of common stock under espp | 0 | 1,757 |
| Other financing activities | 1 | -360 |
| Net cash provided by financing activities | 102 | 2,644 |
| Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents | -127,022 | -12,417 |
| Cash and cash equivalents at beginning of period | 318,695 | - |
| Cash and cash equivalents at end of period | 179,256 | - |
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)